MetLife, Inc. (NYSE:MET) shares were trading lower by -0.31 percent ($-0.16) at $51.84 a piece in Wednesday’s session. It had closed the previous session at $52. MET trades with a P/S ratio of 0.94. This is lower than the both industry’s 1.56 and the wider sector’s 5.89. A low price-to-sales ratio, typically less than 1.0, is considered a good value. Also, it has an estimated price-earnings (P/E) multiple of 10.87 and a trailing 12-month price-earnings (P/E) multiple of 113.93. Shares of MET have uptrended 10.42% in the past three months, while the S&P 500 has moved 4.01% in that time. MetLife, Inc. (MET) has a market cap of $55.19 billion and over the last 12 months, MetLife, Inc. (NYSE:MET) has gone stronger by 6.8%. During the last 52 weeks, the (NYSE:MET) price has been as high as $55.91 and as low as $44.18. MetLife, Inc. earnings have declined with an annualized rate of -35.7% over the last 5 years. The average 1-year price target for MetLife, Inc. (MET) — averaging the work of different analysts — reveals a mean PT of $55.93/share. That’s a potential 7.89 increase relative to where MetLife, Inc. (NYSE:MET) has been trading recently. The current price is seen ranging between $51 and $52.19. There are brokerage firms with lower targets than the average, including one setting a price target of $47. And then on the other side of the spectrum one analyst entrenched in the bullish camp has a target as high as $62. The collective rating of 2.3 for MetLife, Inc. (NYSE:MET) also leans strongly towards the neutral end of the spectrum. Of the 16 analysts surveyed by Reuters that track MET 6 of them rate its stock a hold. The other 10, though not evenly; between analysts who think you should buy MetLife, Inc. versus those who think you should sell it. A 9 analysts rate it as either a buy or a strong buy, while1 believe that investors should either steer clear of MET or, if they already own its stock, sell it. Thermo Fisher Scientific Inc. (TMO) knifed -0.3 percent lower and now trades for $188.51. TMO comes in with a P/S ratio of 3.91 that’s greater than 1, potentially implying that it could be expensive relative to the overall sector (5.07) and its peers (3.06). Also, it has an estimated price-earnings (P/E) multiple of 17.78 and a trailing 12-month price-earnings (P/E) multiple of 32.03. During the last 52 weeks, the price has been as high as $201.2 and as low as $139.07. Thermo Fisher Scientific Inc. (NYSE:TMO) earnings have declined with a quarterly rate of % over the last 5 years. Shares of TMO have sank % in the past three monthswhile the has gained 4.12% in that time. Thermo Fisher Scientific Inc. (NYSE:TMO) has a market cap of $77.5 billion and over the last 12 months, TMO has risen by 26.81%. The average 1-year price target for (TMO) reveals an average price target of $215.13 per share. That’s a potential 14.12 gain from where (NYSE:TMO) has been trading recently. There are brokerage firms with lower targets than the average, including one setting a price target of $172. And then on the other side of the spectrum one analyst entrenched in the bullish camp has a target as high as $230. The consensus recommendation — averaging the work of 15 analysts — of 1.5 for Thermo Fisher Scientific Inc. (TMO) points to bullish case. Of the analysts surveyed by Reuters that track Thermo Fisher Scientific Inc. 1 of them rate its stock a hold. The other 14 are split, though not evenly, between analysts who think you should buy its stock versus those who think you should sell it. A 14 analysts rate it as either a buy or a strong buy, while 0 believe that investors should either steer clear of (NYSE:TMO) or, if they already own its stock, sell it.




(adsbygoogle = window.adsbygoogle || []).push({});
